Abstract
Background: Children with nonclassical congenital adrenal hyperplasia (NCCAH) often present increased growth velocity secondary to elevation of adrenal androgens that accelerates bone maturation and might compromise adult height (AH). Objective: The aim of the study was to analyze prognostic factors affecting growth trajectory (GT) and AH in children with NCCAH. Methods: The study was a retrospective, multicentric study. The study population consisted of 192 children with a confirmed molecular diagnosis of NCCAH, followed by pediatric endocrinology centers from diagnosis up to AH. Clinical records were collected and analyzed. AH (standard deviation score; SDS), pubertal growth (PG) (cm), GT from diagnosis to AH (SDS), and AH adjusted to target height (TH) (AH-TH SDS) were evaluated as outcome indicators using stepwise linear regression models. Results: The stepwise linear regression analysis showed that AH and AH-TH were significantly related to chronological age (CA) (p = 0.008 and 0.016), bone age (BA)/CA ratio (p = 0.004 and 0.001), height (H) (p < 0.001 for both parameters) at NCCAH diagnosis, and TH (p = 0.013 and <0.001). PG was higher in males than in females (22.59 ± 5.74 vs. 20.72 ± 17.4 cm, p = 0.002), as physiologically observed, and was positively related to height (p = 0.027), negatively to BMI (p = 0.001) and BA/CA ratio (p = 0.001) at NCCAH diagnosis. Gender, genotype, biochemical data, and hydrocortisone treatment did not significantly impair height outcomes of these NCCAH children. Conclusions: The results of this study suggest that AH and GT of NCCAH patients are mainly affected by the severity of phenotype (CA, BA/CA ratio, and H) at the time of diagnosis.
Journal Section:
Editor's choice
References
1.
Einaudi
S
, Napolitano
E
, Restivo
F
, Motta
G
, Baldi
M
, Tuli
G
, . Genotype, phenotype and hormonal levels correlation in non-classical congenital adrenal hyperplasia
. J Endocrinol Invest
. 2011
;34
(9
):660
–4
.2.
Wasniewska
M
, Di Pasquale
G
, Rulli
I
, Salzano
G
, Caruso
M
, Indovina
S
, . In sicilian ethnic group non-classical congenital adrenal hyperplasia is frequently associated with a very mild genotype
. J Endocrinol Invest
. 2007
;30
(3
):181
–5
.3.
Gialluisi
A
, Menabò
S
, Baldazzi
L
, Casula
L
, Meloni
A
, Farci
MC
, . A genetic epidemiology study of congenital adrenal hyperplasia in Italy
. Clin Genet
. 2018 Feb
;93
(2
):223
–7
.4.
Balsamo
A
, Cacciari
E
, Baldazzi
L
, Tartaglia
L
, Cassio
A
, Mantovani
V
, . CYP21 analysis and phenotype/genotype relationship in the screened population of the Italian Emilia-Romagna region
. Clin Endocrinol
. 2000
;53
(1
):117
–25
.5.
Azziz
R
, Owerbach
D
. Molecular abnormalities of the 21-hydroxylase gene in hyperandrogenic women with an exaggerated 17-hydroxyprogesterone response to short-term adrenal stimulation
. Am J Obstet Gynecol
. 1995
;172
(3
):914
–8
.6.
New
MI
. Extensive clinical experience: nonclassical 21-hydroxylase deficiency
. J Clin Endocrinol Metab
. 2006
;91
(11
):4205
–14
.7.
White
PC,
, Speiser
PW
,. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
. Endocr Rev
. 2000
;21
(3
):245
–91
.8.
Savaş-Erdeve
Ş
, Çetinkaya
S
, Abalı
ZY
, Poyrazoğlu
Ş
, Baş
F
, Berberoğlu
M
, . Clinical, biochemical and genetic features with nonclassical 21-hydroxylase deficiency and final height
. J Pediatr Endocrinol Metab
. 2017
;30
(7
):759
–66
.9.
Balsamo
A
, Wasniewska
M
, Di Pasquale
G
, Salzano
G
, Baronio
F
, Bombaci
S
, . Birth length and weight in congenital adrenal hyperplasia according to the different phenotypes
. Eur J Pediatr
. 2006
;165
(6
):380
–3
.10.
Nordenström
A
, Falhammar
H
. Diagnosis and management of the patient with non-classic CAH due to 21-hydroxylase deficiency
. Eur J End
. 2019
;180
:127
–45
.11.
Wasniewska
M
, Raiola
G
, Galati
MC
, Salzano
G
, Rulli
I
, Zirilli
G
, . Non-classical 21-hydroxylase deficiency in boys with prepubertal or pubertal gynecomastia
. Eur J Pediatr
. 2008
;167
(9
):1083
–4
.12.
Eyal
O
, Tenenbaum-Rakover
Y
, Shalitin
S
, Israel
S
, Weintrob
N
. Adult height of subjects with nonclassical 21-hydroxylase deficiency
. Acta Paediatr
. 2013
;102
(4
):419
–23
.13.
Pijnenburg-Kleizen
KJ
, Borm
GF
, Otten
BJ
, Schott
DA
, van den Akker
EL
, Stokvis-Brantsma
WH
, . Absence of clinically relevant growth acceleration in untreated children with non-classical congenital adrenal hyperplasia
. Horm Res Paediatr
. 2012
;77
(3
):164
–9
.14.
Juan
L
, Huamei
M
, Zhe
S
, Yanhong
L
, Hongshan
C
, Qiuli
C
, . Near-final height in 82 Chinese patients with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency: a single-center study from China
. J Pediatr Endocrinol Metab
. 2016
;29
(7
):841
–8
.15.
Kohn
B
, Levine
LS
, Pollack
MS
, Pang
S
, Lorenzen
F
, Levy
D
, . Late-onset steroid 21-hydroxylase deficiency: a variant of classical congenital adrenal hyperplasia
. J Clin Endocrinol Metab
. 1982
;55
(5
):817
–27
.16.
Azziz
R
, Dewailly
D
. Diagnosis, screening, and treatment of nonclassic 21-hydroxylase deficiency
. In: Azziz
R
, Nestler
JE
, Dewailly
D
, editors. Androgen excess disorders in women
. Philadelphia
: Lippincott-Raven
; 1997
. p. 181
–92
.17.
Clayton
PE
, Miller
WL
, Oberfield
SE
, Ritzén
EM
, Sippell
WG
, Speiser
PW
. Consensus statement on 21-hydroxylase deficiency from the European society for paediatric endocrinology and the Lawson Wilkins Pediatric endocrine society
. Horm Res
. 2002
;58
(4
):188
–95
.18.
Speiser
PW
, Arlt
W
, Auchus
RJ
, Baskin
LS
, Conway
GS
. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline
. J Clin End Metab
. 2018
;103
:4043
–88
. 19.
Cacciari
E
, Milani
S
, Balsamo
A
, Spada
E
, Bona
G
, Cavallo
L
, . Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr)
. J Endocrinol Invest
. 2006
;29
(7
):581
–93
.20.
Greulich
WW
, Pyle
SI
, Stanford
CA
. Radiographic Atlas of skeletal development of the hand and wrist
. 2nd ed. Palo Alto, CA
: Stanford University Press
; 1959
.21.
Marshall
WA
, Tanner
JM
. Variations in pattern of pubertal changes in girls
. Arch Dis Child
. 1969
;44
(235
):291
–303
.22.
Marshall
WA
, Tanner
JM
. Variations in the pattern of pubertal changes in boys
. Arch Dis Child
. 1970
;45
(239
):13
–23
.23.
Balsamo
A
, Baldazzi
L
, Menabò
S
, Cicognani
A
. Impact of molecular genetics on congenital adrenal hyperplasia management
. Sex Dev
. 2010 Sep
;4
(4–5
):233
–48
.24.
Weintrob
N
, Dickerman
Z
, Sprecher
E
, Galatzer
A
, Pertzelan
A
. Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height
. Eur J Endocrinol
. 1997
;136
(2
):188
–95
.25.
Bizzarri
C
, Improda
N
, Maggioli
C
, Capalbo
D
, Roma
S
, Porzio
O
, . Hydrocortisone therapy and growth trajectory in children with classical congenital adrenal hyperplasia
. Endocr Pract
. 2017
;23
(5
):546
–56
.26.
Falhammar
H
, Nordenström
A
. Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome
. Endocrine
. 2015
;50
(1
):32
–50
.27.
Balsamo
A
, Cicognani
A
, Baldazzi
L
, Barbaro
M
, Baronio
F
, Gennari
M
, . CYP21 Genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency
. J Clin Endocrinol Metab
. 2003
;88
(12
):5680
–8
.28.
Nandagopal
R
, Sinaii
N
, Avila
NA
, Van Ryzin
C
, Chen
W
, Finkielstain
GP
, . Phenotypic profiling of parents with cryptic nonclassic congenital adrenal hyperplasia: findings in 145 unrelated families
. Eur J Endocrinol
. 2011
;164
(6
):977
–84
.29.
Ayalon-Dangur
I
, Segev-Becker
A
, Ayalon
I
, Eyal
O
, Israel
S
, Weintrob
N
. The many faces of non-classic congenital adrenal hyperplasia
. Isr Med Assoc J
. 2017 May
;19
(5
):317
–22
.30.
Weintrob
N
, Brautbar
C
, Pertzelan
A
, Josefsberg
Z
, Dickerman
Z
, Kauschansky
A
, . Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency
. Eur J Endocrinol
. 2000
;143
(3
):397
–403
.31.
Wilson
RC
, Mercado
AB
, Cheng
KC
, New
MI
. Steroid 21-hydroxylase deficiency: genotype may not predict phenotype
. J Clin Endocrinol Metab
. 1995
;80
(8
):2322
–9
.32.
Eugster
EA
, Dimeglio
LA
, Wright
JC
, Freidenberg
GR
, Seshadri
R
, Pescovitz
OH
. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis
. J Pediatr
. 2001
;138
(1
):26
–32
.33.
Ventura
A
, Brunetti
G
, Colucci
S
, Oranger
A
, Ladisa
F
, Cavallo
L
, . Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency
. Biomed Res Int
. 2013
;2013
:250462
.34.
Delvecchio
M
, Soldano
L
, Lonero
A
, Ventura
A
, Giordano
P
, Cavallo
L
, . Evaluation of impact of steroid replacement treatment on bone health in children with 21-hydroxylase deficiency
. Endocrine
. 2015 Apr
;48
(3
):995
–1000
.35.
Speiser
PW
, Dupont
B
, Rubinstein
P
, Piazza
A
, Kastelan
A
, New
MI
. High frequency of nonclassical steroid 21-hydroxylase deficiency
. Am J Hum Genet
. 1985
;37
(4
):650
–67
.36.
Speiser
PW
, Dupont
J
, Zhu
D
, Serrat
J
, Buegeleisen
M
, Tusie-Luna
MT
, . Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency
. J Clin Invest
. 1992
;90
(2
):584
–95
.37.
Trapp
CM
, Oberfield
SE
. Recommendations for treatment of nonclassic congenital adrenal Hyperplasia (NCCAH): an Update
. Steroids
. 2012
;77
(4
):342
–6
.© 2020 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2020
You do not currently have access to this content.
